Clinical Trials Logo

Filter by:
NCT ID: NCT00866970 Completed - Fatigue Clinical Trials

Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia

Start date: September 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to asses the safety and efficacy of ALD518 in patients with Non-Small Cell Lung Cancer-Related Fatigue and cachexia (weight-loss).

NCT ID: NCT00865709 Completed - Clinical trials for Metastatic Colorectal Cancer

Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects

Start date: March 2009
Phase: Phase 2
Study type: Interventional

To determine if sorafenib when added to chemotherapy will slow disease progression more than chemotherapy alone in patients previously untreated for metastatic colorectal cancer.

NCT ID: NCT00865592 Terminated - Type 2 Diabetes Clinical Trials

Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus

Start date: March 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate that dutogliptin/PHX1149T is safe and tolerable.

NCT ID: NCT00865579 Terminated - Parkinson's Disease Clinical Trials

Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients

Start date: April 2009
Phase: Phase 3
Study type: Interventional

Parkinson's Disease (PD) is a major neurodegenerative disorder in which there is a progressive loss of dopamine-containing neurons. The understanding that PD is a syndrome of dopamine (DA) deficiency led to the introduction in the clinical practice of L-dopa, a precursor of DA that crosses the blood brain barrier, and also to the use of selective inhibitors of MAO-B, the major DA metabolising enzyme in humans. Safinamide is an inhibitor of MAO-B. This study is to evaluate the long term safety and tolerability of safinamide in PD patients, that have already completed a previous clinical study with Safinamide. The physical and neurological conditions as well as other safety parameters will get compared from baseline to subsequent visits.

NCT ID: NCT00864825 Completed - Schizophrenia Clinical Trials

Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia

Start date: August 2009
Phase: Phase 4
Study type: Interventional

The objective of the study is to evaluate the efficacy of allopurinol, compared to placebo, as add-on to anti-psychotics in the treatment of patients with schizophrenia.

NCT ID: NCT00864097 Terminated - Osteoarthritis Clinical Trials

Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip

Start date: August 11, 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the analgesic efficacy and safety of tanezumab added on to diclofenac SR in patients with osteoarthritis of the knee or hip currently experiencing partial benefit from, and are tolerating, diclofenac 150 mg/day therapy.

NCT ID: NCT00863239 Completed - Clinical trials for Hepatitis C, Chronic

Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV

SELECT-2
Start date: March 2009
Phase: Phase 2
Study type: Interventional

The purpose of the study was to assess in subjects with chronic hepatitis C (treatment-naïve, genotype 1) receiving weight-based doses of ribavirin the virologic response to 3 dose levels of Locteron™, dosed every 2 weeks, in comparison with PEG-Intron™ dosed weekly.

NCT ID: NCT00861614 Completed - Prostate Cancer Clinical Trials

Study of Immunotherapy to Treat Advanced Prostate Cancer

Start date: May 2009
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine if advanced prostate cancer patient s that are treated with radiotherapy (RT) plus ipilimumab live longer that those treated with RT alone

NCT ID: NCT00860288 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

Start date: February 2009
Phase: Phase 2/Phase 3
Study type: Interventional

This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as add-on therapy to metformin

NCT ID: NCT00860262 Completed - Hypertension Clinical Trials

Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension

Start date: March 2009
Phase: Phase 3
Study type: Interventional

The primary objective of this trial is to demonstrate that following eight weeks of treatment the FDC of telmisartan 80 mg plus amlodipine 10 mg (T80/A10) is superior as first line therapy in reducing mean seated trough cuff Systolic Blood Pressure [SBP] compared to the monotherapies of telmisartan 80 mg (T80) and amlodipine 10 mg (A10) in patients with severe hypertension. A key secondary objective is to identify the duration of treatment required to demonstrate the superiority of the FDC over both of the monotherapies.